治疗子痫前期的生物标志物和护理点筛查方法。

IF 5.4 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Ka Wai Ng, Nandita Chaturvedi, Gerard L. Coté, Stephanie A. Fisher, Samuel Mabbott
{"title":"治疗子痫前期的生物标志物和护理点筛查方法。","authors":"Ka Wai Ng, Nandita Chaturvedi, Gerard L. Coté, Stephanie A. Fisher, Samuel Mabbott","doi":"10.1038/s43856-024-00642-4","DOIUrl":null,"url":null,"abstract":"Preeclampsia is a multi-organ pregnancy complication, that is primarily detected when pregnant people have high blood pressure, and is confirmed by testing for the presence of protein in the urine. While more specific and accurate diagnostic and imaging tests are becoming available, they are still in the process of undergoing widespread regulatory adoption, and so are not yet the standard of care. Since biochemical processes are a precursor to the systemic progression of disease, we review some established, emerging, and promising biomarkers that are proposed to be associated with preeclampsia, and newly developed approaches for screening them at the point of care, to reduce the burden of the disease. Ng, Chaturvedi et al. discuss established, emerging, and promising biomarkers related to preeclampsia. They highlight novel approaches for screening these biomarkers at the point of care, aiming to democratize testing and reduce the burden of the disease.","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":null,"pages":null},"PeriodicalIF":5.4000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493996/pdf/","citationCount":"0","resultStr":"{\"title\":\"Biomarkers and point of care screening approaches for the management of preeclampsia\",\"authors\":\"Ka Wai Ng, Nandita Chaturvedi, Gerard L. Coté, Stephanie A. Fisher, Samuel Mabbott\",\"doi\":\"10.1038/s43856-024-00642-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Preeclampsia is a multi-organ pregnancy complication, that is primarily detected when pregnant people have high blood pressure, and is confirmed by testing for the presence of protein in the urine. While more specific and accurate diagnostic and imaging tests are becoming available, they are still in the process of undergoing widespread regulatory adoption, and so are not yet the standard of care. Since biochemical processes are a precursor to the systemic progression of disease, we review some established, emerging, and promising biomarkers that are proposed to be associated with preeclampsia, and newly developed approaches for screening them at the point of care, to reduce the burden of the disease. Ng, Chaturvedi et al. discuss established, emerging, and promising biomarkers related to preeclampsia. They highlight novel approaches for screening these biomarkers at the point of care, aiming to democratize testing and reduce the burden of the disease.\",\"PeriodicalId\":72646,\"journal\":{\"name\":\"Communications medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2024-10-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493996/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Communications medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.nature.com/articles/s43856-024-00642-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Communications medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.nature.com/articles/s43856-024-00642-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

子痫前期是一种多器官妊娠并发症,主要是在孕妇出现高血压时被发现,并通过检测尿液中是否含有蛋白质来确认。虽然越来越多的特异性和准确的诊断和成像检测方法已经问世,但这些方法仍在监管部门的广泛采用过程中,因此尚未成为治疗标准。由于生化过程是疾病全身进展的前兆,我们回顾了一些已确定的、新出现的和有希望的与子痫前期相关的生物标志物,以及新开发的在护理点筛查这些生物标志物的方法,以减轻疾病负担。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Biomarkers and point of care screening approaches for the management of preeclampsia

Biomarkers and point of care screening approaches for the management of preeclampsia
Preeclampsia is a multi-organ pregnancy complication, that is primarily detected when pregnant people have high blood pressure, and is confirmed by testing for the presence of protein in the urine. While more specific and accurate diagnostic and imaging tests are becoming available, they are still in the process of undergoing widespread regulatory adoption, and so are not yet the standard of care. Since biochemical processes are a precursor to the systemic progression of disease, we review some established, emerging, and promising biomarkers that are proposed to be associated with preeclampsia, and newly developed approaches for screening them at the point of care, to reduce the burden of the disease. Ng, Chaturvedi et al. discuss established, emerging, and promising biomarkers related to preeclampsia. They highlight novel approaches for screening these biomarkers at the point of care, aiming to democratize testing and reduce the burden of the disease.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信